CRISPR genome-editing biopharma firm Caribou Biosciences (NSDQ:CRBU) has appointed Nancy Whiting to its board of directors.
Whiting had previously worked at Seagen (formerly known as Seattle Genetics) for 14 years and had three years of experience at GSK. At Seagen, she was involved in the development of several drugs, including Adcetris, Padcev, Tukysa, tisotumab vedotin and ladiratizumab vedotin.
Seagen has developed a chRDNA genome-editing platform that supports multiple genome edits. In addition, the company is working on a range of chRDNA-based cell therapies.
Whiting has “significant experience in all phases of drug development and commercialization with particular expertise in oncology, which is highly relevant to Caribou as we advance our pipeline of chRDNA-edited allogeneic cell therapies for the potential treatment of a variety of hematologic malignancies and solid tumors,” said Rachel Haurwitz, CEO of Caribou Biosciences, in a statement.
Whiting has received a Pharm.D. degree from the University of Washington and a bachelor’s degree in pharmacy from the University of British Columbia, Vancouver.
Berkeley, Calif.–based Caribou went public in July, raising $304 million in the process.
Filed Under: Drug Discovery
